Ohio Police Shoot and Kill Unarmed Black Man

Sep.01.2022
Ohio Police Shoot and Kill Unarmed Black Man
Ohio cop fatally shoots an unarmed 20-year-old black man holding an e-cigarette, mistaken for a gun, sparking investigations.

A police officer in Ohio fatally shot a 20-year-old black male who was holding an electronic cigarette and raised his hands. The police thought it was a gun.


At a press conference held several hours later, Police Chief Elaine Bryant played body camera footage. The video showed police arriving at an apartment on Sullivan Avenue around 2:30 am to serve an arrest warrant for Lewis, who was wanted for assault. Police waited outside the front door for about 10 minutes before two men emerged and were detained, but there was no sign of Lewis initially. Police then sent in a barking K-9 dog and followed it into the home. Moments later, K-9 Officer Ricky Anderson opened the bedroom door and found Lewis in bed, where he was immediately shot and killed.


According to Bryant, a frame-by-frame review of the video shows that Lewis appeared to have "something" in his hand as he raised his hands when police opened the door and pointed their guns at him.


Kobe stated that no firearms were found on the scene, but an electronic vaping device was discovered on the bed.


According to the Columbus Dispatch, after being shot, the dying Lewis was ordered to "get up" from his bed, then handcuffed and removed from the apartment. After receiving CPR on scene, Lewis was taken to OhioHealth Grant Medical Center where he died within an hour. The chief did not comment on whether authorities believed Lewis had a weapon in his possession, a question that is expected to be resolved by the investigation launched by the Ohio Bureau of Criminal Investigation.


Kobe expressed sympathy and sadness for Donovan Lewis' mother upon his passing. He also expressed sorrow for the community, but stated that they will allow the investigation to proceed. As the newly hired official, he emphasized the city's commitment to holding any officials responsible for any wrongdoing, but stressed that a national investigation must be conducted first.


Disclaimer: 1. The content of this article is compiled from third-party information, and is intended solely for industry exchange and learning purposes. 2. This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the accuracy and authenticity of the content. The compilation of this article is for industry exchange and research only. 3. Due to limitations in the level of compilation, the content may differ from the original. Please refer to the original article for accuracy. 4. 2FIRSTS fully aligns with the Chinese government regarding any statements and positions related to domestic, Hong Kong, Macao, Taiwan, and foreign matters. 5. The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.
Feb.11
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai
Malaysia health minister says court conviction over vape promotion sets key precedent for Act 852 enforcement
Malaysia health minister says court conviction over vape promotion sets key precedent for Act 852 enforcement
Malaysia’s Health Minister Datuk Seri Dr Dzulkefly Ahmad said the Putrajaya Magistrate’s Court decision to convict a known personality for promoting vape has set an important legal precedent for enforcing the Control of Smoking Products for Public Health Act (Act 852).
Jan.09 by 2FIRSTS.ai
Florida AG announces largest illegal vape seizure in state history, 2,183 contraband devices seized
Florida AG announces largest illegal vape seizure in state history, 2,183 contraband devices seized
Florida’s attorney general announced a record-breaking statewide enforcement push against illegal vaping products, with four joint operations seizing 2,183 contraband vapes and additional nitrous oxide-related items. Regulators also reported removing thousands of noncompliant products from store shelves, while investigations remain ongoing.
Feb.09 by 2FIRSTS.ai
South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
South Korea’s National Health Insurance Service (NHIS) has again lost on appeal in its damages lawsuit against KT&G, Philip Morris Korea and BAT Korea, seeking ₩53.3 billion (about $36.244 million).
Jan.15 by 2FIRSTS.ai
U.S. FDA Posts Final ZYN MRTP Materials, Sets March 4 Deadline for Public Comments
U.S. FDA Posts Final ZYN MRTP Materials, Sets March 4 Deadline for Public Comments
U.S. FDA has released the final batch of materials for ZYN MRTP applications and set March 4 (11:59 p.m. ET) as the deadline for public comments to be considered in the agency’s review.
Feb.03 by 2FIRSTS.ai